Adrian A N Doevelaar1, Martin Bachmann2, Bodo Hölzer1, Felix S Seibert1, Benjamin J Rohn1, Frederic Bauer1, Oliver Witzke3, Ulf Dittmer4, Michael Bachmann5, Serap Yilmaz2, Rita Dittmer6, Sonja Schneppenheim6, Nina Babel1, Ulrich Budde6, Timm H Westhoff1. 1. Medical Department I, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. 2. Department of Intensive Care and Ventilatory Medicine, Asklepios Klinikum Hamburg Harburg, Hamburg, Germany. 3. Department of Infectiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. 4. Department of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. 5. Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI. 6. Department of Hemostaseology, MEDILYS Laborgesellschaft mbH, Hamburg, Germany.
Abstract
OBJECTIVES: Prevention and therapy of immunothrombosis remain crucial challenges in the management of coronavirus disease 2019, since the underlying mechanisms are incompletely understood. We hypothesized that endothelial damage may lead to substantially increased concentrations of von Willebrand factor with subsequent relative deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). DESIGN: Prospective controlled cross-over trial. SETTING: Blood samples of patients with confirmed coronavirus disease 2019 and healthy controls were obtained in three German hospitals and analyzed in a German hemostaseologic laboratory. PATIENTS: Seventy-five patients with confirmed coronavirus disease 2019 of mild to critical severity and 30 healthy controls. MEASUREMENTS AND MAIN RESULTS: von Willebrand factor antigen, ADAMTS13, and von Willebrand factor multimer formation were analyzed. von Willebrand factor antigen was 4.1 times higher in COVID-19 patients compared with healthy controls (p < 0.0001), whereas ADAMTS13 activities were not significantly different (p = 0.18). The ADAMTS13/von Willebrand factor antigen ratio was significantly lower in COVID-19 than in the control group (24.4 ± 20.5 vs 82.0 ± 30.7; p < 0.0001). Fourteen patients (18.7%) undercut a critical ratio of 10 as described in thrombotic thrombocytopenic purpura. Gel analysis of multimers resembled a thrombotic thrombocytopenic purpura pattern with loss of the largest multimers in 75% and a smeary triplet pattern in 39% of the patients. The ADAMTS13/von Willebrand factor antigen ratio decreased continuously from mild to critical disease (analysis of variance p = 0.026). Furthermore, it differed significantly between surviving patients and those who died from COVID-19 (p = 0.001) yielding an area under the curve of 0.232 in receiver operating characteristic curve curve analysis. CONCLUSION: COVID-19 is associated with a substantial increase in von Willebrand factor levels, which can exceed the ADAMTS13 processing capacity resulting in the formation of large von Willebrand factor multimers indistinguishable from thrombotic thrombocytopenic purpura. The ADAMTS13/von Willebrand factor antigen ratio is an independent predictor of severity of disease and mortality. These findings provide a rationale to consider plasma exchange as a therapeutic option in COVID-19 and to include von Willebrand factor and ADAMTS13 in the diagnostic workup.
OBJECTIVES: Prevention and therapy of immunothrombosis remain crucial challenges in the management of coronavirus disease 2019, since the underlying mechanisms are incompletely understood. We hypothesized that endothelial damage may lead to substantially increased concentrations of von Willebrand factor with subsequent relative deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). DESIGN: Prospective controlled cross-over trial. SETTING: Blood samples of patients with confirmed coronavirus disease 2019 and healthy controls were obtained in three German hospitals and analyzed in a German hemostaseologic laboratory. PATIENTS: Seventy-five patients with confirmed coronavirus disease 2019 of mild to critical severity and 30 healthy controls. MEASUREMENTS AND MAIN RESULTS:von Willebrand factor antigen, ADAMTS13, and von Willebrand factor multimer formation were analyzed. von Willebrand factor antigen was 4.1 times higher in COVID-19patients compared with healthy controls (p < 0.0001), whereas ADAMTS13 activities were not significantly different (p = 0.18). The ADAMTS13/von Willebrand factor antigen ratio was significantly lower in COVID-19 than in the control group (24.4 ± 20.5 vs 82.0 ± 30.7; p < 0.0001). Fourteen patients (18.7%) undercut a critical ratio of 10 as described in thrombotic thrombocytopenic purpura. Gel analysis of multimers resembled a thrombotic thrombocytopenic purpura pattern with loss of the largest multimers in 75% and a smeary triplet pattern in 39% of the patients. The ADAMTS13/von Willebrand factor antigen ratio decreased continuously from mild to critical disease (analysis of variance p = 0.026). Furthermore, it differed significantly between surviving patients and those who died from COVID-19 (p = 0.001) yielding an area under the curve of 0.232 in receiver operating characteristic curve curve analysis. CONCLUSION:COVID-19 is associated with a substantial increase in von Willebrand factor levels, which can exceed the ADAMTS13 processing capacity resulting in the formation of large von Willebrand factor multimers indistinguishable from thrombotic thrombocytopenic purpura. The ADAMTS13/von Willebrand factor antigen ratio is an independent predictor of severity of disease and mortality. These findings provide a rationale to consider plasma exchange as a therapeutic option in COVID-19 and to include von Willebrand factor and ADAMTS13 in the diagnostic workup.
Authors: Kristin M Corey; Lyra B Olson; Ibtehaj A Naqvi; Sarah A Morrison; Connor Davis; Shahid M Nimjee; Loretta G Que; Robin E Bachelder; Bryan D Kraft; Lingye Chen; Smita K Nair; Jerrold H Levy; Bruce A Sullenger Journal: Anesthesiology Date: 2022-07-01 Impact factor: 8.986
Authors: Soracha E Ward; Helen Fogarty; Ellie Karampini; Michelle Lavin; Sonja Schneppenheim; Rita Dittmer; Hannah Morrin; Siobhan Glavey; Cliona Ni Cheallaigh; Colm Bergin; Ignacio Martin-Loeches; Patrick W Mallon; Gerard F Curley; Ross I Baker; Ulrich Budde; Jamie M O'Sullivan; James S O'Donnell Journal: J Thromb Haemost Date: 2021-06-20 Impact factor: 16.036
Authors: Diana A Gorog; Robert F Storey; Paul A Gurbel; Udaya S Tantry; Jeffrey S Berger; Mark Y Chan; Daniel Duerschmied; Susan S Smyth; William A E Parker; Ramzi A Ajjan; Gemma Vilahur; Lina Badimon; Jurrien M Ten Berg; Hugo Ten Cate; Flora Peyvandi; Taia T Wang; Richard C Becker Journal: Nat Rev Cardiol Date: 2022-01-13 Impact factor: 49.421
Authors: Anastasiya S Babkina; Irina V Ostrova; Mikhail Ya Yadgarov; Artem N Kuzovlev; Andrey V Grechko; Alexey V Volkov; Arkady M Golubev Journal: Viruses Date: 2022-01-21 Impact factor: 5.048
Authors: Julius J Schmidt; Dan Nicolae Borchina; Mariet Van't Klooster; Khalida Bulhan-Soki; Reuben Okioma; Larissa Herbst; Diego Sandoval Rodríguez; Vedran Premužić; Stefan Büttner; Birgit Bader; Wojciech Serednicki; Ewa Zasada; Michael Schmitz; Ralf A Quabach; Maria Hrincheva; Thomas Fühner; Jan T Kielstein Journal: Nephrol Dial Transplant Date: 2022-03-25 Impact factor: 5.992
Authors: David M Smadja; Steven J Mentzer; Michaela Fontenay; Mike A Laffan; Maximilian Ackermann; Julie Helms; Danny Jonigk; Richard Chocron; Gerald B Pier; Nicolas Gendron; Stephanie Pons; Jean-Luc Diehl; Coert Margadant; Coralie Guerin; Elisabeth J M Huijbers; Aurélien Philippe; Nicolas Chapuis; Patrycja Nowak-Sliwinska; Christian Karagiannidis; Olivier Sanchez; Philipp Kümpers; David Skurnik; Anna M Randi; Arjan W Griffioen Journal: Angiogenesis Date: 2021-06-28 Impact factor: 9.596
Authors: Johannes Ruhe; Ulf Schnetzke; Karim Kentouche; Florian Prims; Michael Baier; Konstantin Herfurth; Mandy Schlosser; Martin Busch; Andreas Hochhaus; Gunter Wolf Journal: Ann Hematol Date: 2021-07-26 Impact factor: 3.673